InvestorsHub Logo
Followers 240
Posts 12420
Boards Moderated 0
Alias Born 08/14/2003

Re: FDApproved post# 33147

Tuesday, 04/21/2020 6:15:11 PM

Tuesday, April 21, 2020 6:15:11 PM

Post# of 44784
The question that certainly would be asked is, if the volume for the drug expanded dramatically by it's becoming part of the SOC for the treatment of pneumonia, would the price come down at all. Actually, even at that price if given prior to hospitalization, if it avoided many hospitalizations, and especially a lot of people being put on ventilators, it would be a substantial cost savings.

I still would like to hear of many more people getting the drug under compassionate use, or perhaps in some nations it's permitted to charge for the drug. Under right to try companies must provide cost information, which nearly all refuse to, in order to charge their production cost. If the FDA and others would settle on say 50% of list price, I believe a great deal of use could be made under right to try, or compassionate use, especially if insurance companies paid for drugs that offered the potential of saving them money in the long run.

I frankly have no idea if most insurance companies are paying for coronavirus coverage, or if Govt. funds are essentially paying all the bills. There is no doubt our National Debt, as well as the debt of most nations around the world will be up dramatically before this is over. Frankly I believe our National Worth is far greater than our National Debt, but people rarely look at an honest appraisal of what all the U.S., or any other nation for that matter, are worth.

I believe all around the world we practice accounting that depreciates all sorts of things that if you went to sell them actually appreciated dramatically.

Gary